| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6117355 | Immunology Letters | 2011 | 6 Pages |
Abstract
⺠This paper evaluates the clinical and economic impact generated by starting ANA dilution at 1:160. ⺠A total of 13,233 samples were processed, and only ANA dilutions of 1:160 and higher showed significantly increased positive predictive value for anti-ENA and anti-dsDNA when compared to 1:40 titer. ⺠The cut-off 1:160 achieved making 17% less ANA tests, 42% less anti-ENA determinations and 36% less anti-dsDNA tests. ⺠Setting the starting dilution of ANA at 1:160 avoids unnecessary studies, increases ANA positive predictive values for anti-ENA and anti-dsDNA, and generates clinical and economic benefits.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Delia Almeida González, Antonio Cabrera de León, Alfredo Roces Varela, Miriam GarcÃa GarcÃa, Marta de Sequera Rahola, MarÃa del Cristo RodrÃguez Pérez, Ana González Hernández, MarÃa José Falcón Falcón, Buenaventura Brito DÃaz,